目的 观察百令胶囊联合氟替美维的治疗稳定期慢性阻塞性肺疾病（慢阻肺）的临床效果。方法 前瞻性选取150例稳定期慢阻肺患者，均为河南大学第一附属医院于2023年2月—2025年2月收治，根据随机数字表法分为对照组和治疗组，每组各75例。对照组吸入氟替美维吸入粉雾剂，1吸/次，1次/d。治疗组在对照组基础上口服百令胶囊，4粒/次，3次/d。两组患者连续治疗3个月。观察两组治疗效果、治疗前后慢性阻塞性肺疾病测试量表（CAT）、急性发作次数、用力肺活量（FVC）、第1秒用力呼气容积（FEV1）、呼气峰流速（PEF）、第1秒率（FEV1/FVC），及免疫球蛋白（Ig）A、IgM、IgG水平。结果 治疗后，治疗组总有效率（94.67%）显著高于对照组（80.00%，P＜0.05）。治疗1、3个月后，两组CAT评分和急性发作次数较治疗前显著降低（P＜0.05），且治疗组患者CAT评分和急性发作次数均低于同期对照组（P＜0.05）。治疗1、3个月后，两组FEV1、FVC、PEF、FEV1/FVC较治疗前显著升高（P＜0.05），且治疗组患者肺功能明显好于同期对照组（P＜0.05）。治疗1、3个月后，两组IgA、IgM、IgG水平较治疗前逐渐升高（P＜0.05）；治疗后，治疗组IgA、IgM、IgG水平好于同期对照组（P＜0.05）。结论 百令胶囊联合氟替美维治疗稳定期慢阻肺患者效果显著，能改善肺功能与免疫功能，缓解患者病情，减少病情发作，安全性较好。

Objective To observe the clinical efficacy of Bailing Capsules combined with fluticasone furoate, umeclidinium bromide and vilanterol trifenatate in the treatment of patients with stable chronic obstructive pulmonary disease (COPD). Methods A total of 150 patients with stable COPD admitted to the First Affiliated Hospital of Henan University from February 2023 to February 2025 were prospectively enrolled and divided into a control group and a treatment group using the random number table method, with 75 cases in each group. The control group received Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate Powder for inhalation, one inhalation each time, once daily. On the basis of the control group, the treatment group was additionally given oral Bailing Capsules, 4 capsules each time, three times a day. Both groups received continuous treatment for 3 months. The clinical efficacy, COPD Assessment Test (CAT) score, frequency of acute exacerbations, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), FEV1/FVC ratio, and serum levels of immunoglobulin A (IgA), IgM and IgG were compared before and after treatment. Results After treatment, the total effective rate of the treatment group was 94.67%, which was significantly higher than 80.00% of the control group (P < 0.05). After 1 and 3 months of treatment, the CAT score and the frequency of acute attacks in two groups were significantly lower than before treatment (P < 0.05), and the CAT score and the frequency of acute attacks in the treatment group were lower than those in control group at same time (P < 0.05). After 1 and 3 months of treatment, FEV1, FVC, PEF, and FEV1/FVC in two groups were significantly higher than before treatment (P < 0.05), and the lung function in the treatment group was significantly better than that in control group at same time (P < 0.05). After 1 and 3 months of treatment, the levels of IgA, IgM and IgG in both groups gradually increased compared to before treatment (P < 0.05). After treatment, the levels of IgA, IgM and IgG in treatment group were better than those in control group at same time (P < 0.05). Conclusion Bailing Capsules combined with fluticasone furoate, umeclidinium bromide and vilanterol trifenatate achieves a remarkable therapeutic effect in patients with stable COPD. This combination can improve pulmonary function and immune function, relieve clinical conditions, reduce acute exacerbations, and possess favorable safety.

R974